Our novel information on the modulation of tamoxifen resistance by this SNHG6-miR-101 axis adds new knowledge, and should further generate interest in the evaluation of miR-101 targeting by SNHG6 in the context of cancer drug resistance. The gene discussed is SNHG6; the disease is cancer.